SG10201502582PA - Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt - Google Patents
Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its saltInfo
- Publication number
- SG10201502582PA SG10201502582PA SG10201502582PA SG10201502582PA SG10201502582PA SG 10201502582P A SG10201502582P A SG 10201502582PA SG 10201502582P A SG10201502582P A SG 10201502582PA SG 10201502582P A SG10201502582P A SG 10201502582PA SG 10201502582P A SG10201502582P A SG 10201502582PA
- Authority
- SG
- Singapore
- Prior art keywords
- rosuvastatin
- salt
- pharmaceutical composition
- olmesartan medoxomil
- medoxomil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120032903 | 2012-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201502582PA true SG10201502582PA (en) | 2015-05-28 |
Family
ID=49260650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405198YA SG11201405198YA (en) | 2012-03-30 | 2013-03-22 | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
| SG10201502582PA SG10201502582PA (en) | 2012-03-30 | 2013-03-22 | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405198YA SG11201405198YA (en) | 2012-03-30 | 2013-03-22 | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20150050333A1 (en) |
| EP (1) | EP2830618B1 (en) |
| JP (1) | JP6122098B2 (en) |
| KR (2) | KR101451081B1 (en) |
| CN (1) | CN104220068B (en) |
| AU (1) | AU2013240846B2 (en) |
| CA (1) | CA2866377C (en) |
| CL (1) | CL2014002581A1 (en) |
| CY (1) | CY1117909T1 (en) |
| DK (1) | DK2830618T3 (en) |
| ES (1) | ES2587912T3 (en) |
| HK (1) | HK1200107A1 (en) |
| HU (1) | HUE030674T2 (en) |
| IN (1) | IN2014MN01919A (en) |
| LT (1) | LT2830618T (en) |
| MX (1) | MX362400B (en) |
| MY (1) | MY166288A (en) |
| PH (2) | PH12014501813B1 (en) |
| PT (1) | PT2830618T (en) |
| RU (1) | RU2616516C2 (en) |
| SG (2) | SG11201405198YA (en) |
| WO (1) | WO2013147462A1 (en) |
| ZA (1) | ZA201407544B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170083071A (en) * | 2014-11-11 | 2017-07-17 | 시오노기 앤드 컴파니, 리미티드 | Multi-layered tablet containing drug unstable to light |
| CA2973362A1 (en) * | 2015-01-09 | 2016-07-14 | Autotelic Llc | Methods for olmesartan dosing by auc |
| CN105232555A (en) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | Telmisartan and rosuvastatin compound preparation and preparation method thereof |
| CN105232556A (en) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | Candesartan cilexetil/ (/b) (b) rosuvastatin (/b) (b) compound preparation and preparation method thereof |
| CN106727580A (en) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | A kind of A Lishatan esters/Rosuvastatin compound preparation and preparation method thereof |
| CN106727579A (en) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | A kind of Irbesartan/Rosuvastatin compound preparation and preparation method thereof |
| CN105395551A (en) * | 2015-11-19 | 2016-03-16 | 哈尔滨圣吉药业股份有限公司 | Olmesartan medoxomil/rosuvastatin compound preparation and preparation method thereof |
| TW201726744A (en) | 2016-01-11 | 2017-08-01 | 奧托德里克有限公司 | Composition, device, and method for detecting OLMESARTAN and improving compliance in treating hypertension |
| WO2018009842A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for rosuvastatin dosing by auc |
| SG11201912482WA (en) * | 2017-07-17 | 2020-02-27 | Lilly Co Eli | Pharmaceutical compositions |
| KR101992400B1 (en) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | Pharmaceutical formulation |
| WO2020175922A2 (en) * | 2019-02-26 | 2020-09-03 | 주식회사 대웅제약 | Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia |
| KR20220026641A (en) * | 2020-08-25 | 2022-03-07 | 주식회사 대웅제약 | A single dosage form of a pharmaceutical composition for the treatment or prevention of hypertension and hyperlipidemia |
| CN113398086A (en) * | 2021-05-18 | 2021-09-17 | 海南通用三洋药业有限公司 | Preparation method of rosuvastatin calcium capsule and rosuvastatin calcium capsule |
| CN113476423A (en) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | Preparation method of rosuvastatin calcium capsule and rosuvastatin calcium capsule |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| JP2002145770A (en) * | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency |
| JP5769362B2 (en) * | 2006-06-27 | 2015-08-26 | 第一三共株式会社 | Compressed preparation |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| KR100985254B1 (en) | 2006-10-30 | 2010-10-04 | 한올바이오파마주식회사 | Controlled release complex composition comprising angiotensin???receptor blockers and HMG-CoA reductase inhibitors |
| WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| CN101594865A (en) * | 2006-12-07 | 2009-12-02 | 第一三共株式会社 | The pharmaceutical composition that contains the low hydroxy propyl cellulose that replaces |
| TWI488658B (en) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | Method for improvement of elution |
| TW200927197A (en) * | 2007-10-29 | 2009-07-01 | Daiichi Sankyo Co Ltd | Film coated preparation |
| US20110009482A1 (en) * | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
| WO2009113420A1 (en) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
| KR20090114190A (en) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | Controlled release complex composition comprising hmg-coa reductase inhibitors and angiotensin-ii-receptor blockers |
| US10574932B2 (en) * | 2008-07-28 | 2020-02-25 | Fox Digital Enterprises, Inc. | System and method of generating subtitling for media |
| JP5827952B2 (en) * | 2009-10-09 | 2015-12-02 | ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． | Pharmaceutical composition having both rapid action and durability |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
| US8399011B1 (en) * | 2012-08-10 | 2013-03-19 | Magnifica Inc. | Oral particle compositions containing a core and an acid-soluble coat |
-
2013
- 2013-03-22 RU RU2014143536A patent/RU2616516C2/en active
- 2013-03-22 CN CN201380018083.0A patent/CN104220068B/en active Active
- 2013-03-22 ES ES13769567.2T patent/ES2587912T3/en active Active
- 2013-03-22 AU AU2013240846A patent/AU2013240846B2/en active Active
- 2013-03-22 EP EP13769567.2A patent/EP2830618B1/en active Active
- 2013-03-22 LT LTEP13769567.2T patent/LT2830618T/en unknown
- 2013-03-22 PT PT137695672T patent/PT2830618T/en unknown
- 2013-03-22 US US14/388,115 patent/US20150050333A1/en not_active Abandoned
- 2013-03-22 CA CA2866377A patent/CA2866377C/en active Active
- 2013-03-22 DK DK13769567.2T patent/DK2830618T3/en active
- 2013-03-22 HU HUE13769567A patent/HUE030674T2/en unknown
- 2013-03-22 SG SG11201405198YA patent/SG11201405198YA/en unknown
- 2013-03-22 JP JP2015503112A patent/JP6122098B2/en active Active
- 2013-03-22 IN IN1919MUN2014 patent/IN2014MN01919A/en unknown
- 2013-03-22 MY MYPI2014002534A patent/MY166288A/en unknown
- 2013-03-22 SG SG10201502582PA patent/SG10201502582PA/en unknown
- 2013-03-22 MX MX2014011510A patent/MX362400B/en active IP Right Grant
- 2013-03-22 KR KR1020130030734A patent/KR101451081B1/en active IP Right Grant
- 2013-03-22 WO PCT/KR2013/002378 patent/WO2013147462A1/en active Application Filing
-
2014
- 2014-06-19 KR KR1020140074778A patent/KR101931195B1/en active IP Right Grant
- 2014-08-11 PH PH12014501813A patent/PH12014501813B1/en unknown
- 2014-09-26 CL CL2014002581A patent/CL2014002581A1/en unknown
- 2014-10-17 ZA ZA2014/07544A patent/ZA201407544B/en unknown
-
2015
- 2015-01-20 HK HK15100605.0A patent/HK1200107A1/en unknown
-
2016
- 2016-03-03 PH PH12016500420A patent/PH12016500420A1/en unknown
- 2016-08-11 CY CY20161100799T patent/CY1117909T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200107A1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| ZA201903516B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1206027A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| EP2886546A4 (en) | Heterocyclic compound and use thereof | |
| AP3611A (en) | Heterocyclic compounds and their uses | |
| ZA201409508B (en) | Pharmaceutical composition comprising fimasartan and hydrochlorothiazide | |
| HK1206350A1 (en) | 2h-imidazol-4-amine compounds and their use as bace inhibitors 2h--4- bace | |
| EP2813508A4 (en) | Heterocyclic compound and use thereof | |
| EP2819713A4 (en) | Water-based wetness-indicating composition and sensor | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors |